- Home
- ARCO vs APGE Comparison
ARCO vs APGE Comparison
Compare ARCO & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- APGE
- Stock Information
- Founded
- ARCO 2007
- APGE 2022
- Country
- ARCO Uruguay
- APGE United States
- Employees
- ARCO N/A
- APGE N/A
- Industry
- ARCO Restaurants
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARCO Consumer Discretionary
- APGE Health Care
- Exchange
- ARCO Nasdaq
- APGE Nasdaq
- Market Cap
- ARCO 1.7B
- APGE 1.8B
- IPO Year
- ARCO 2011
- APGE 2023
- Fundamental
- Price
- ARCO $8.15
- APGE $39.72
- Analyst Decision
- ARCO Buy
- APGE Strong Buy
- Analyst Count
- ARCO 1
- APGE 4
- Target Price
- ARCO $12.00
- APGE $91.33
- AVG Volume (30 Days)
- ARCO 1.4M
- APGE 789.9K
- Earning Date
- ARCO 03-12-2025
- APGE 03-03-2025
- Dividend Yield
- ARCO 2.94%
- APGE N/A
- EPS Growth
- ARCO N/A
- APGE N/A
- EPS
- ARCO 0.71
- APGE N/A
- Revenue
- ARCO $4,470,162,000.00
- APGE N/A
- Revenue This Year
- ARCO $6.53
- APGE N/A
- Revenue Next Year
- ARCO $10.65
- APGE $795.25
- P/E Ratio
- ARCO $11.54
- APGE N/A
- Revenue Growth
- ARCO 3.19
- APGE N/A
- 52 Week Low
- ARCO $7.02
- APGE $29.10
- 52 Week High
- ARCO $11.49
- APGE $68.21
- Technical
- Relative Strength Index (RSI)
- ARCO 51.69
- APGE 55.27
- Support Level
- ARCO $7.98
- APGE $38.18
- Resistance Level
- ARCO $8.19
- APGE $41.07
- Average True Range (ATR)
- ARCO 0.28
- APGE 2.31
- MACD
- ARCO -0.01
- APGE 0.22
- Stochastic Oscillator
- ARCO 54.43
- APGE 63.77
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.